With a median of 5.5 (IQR 4-6, range 4-8) treatments including the anti-PD-1, the most used second line treatment was ESHAP in 12 patients (40%). Hodgkin lymphoma (HL) is a good-prognosis malignancy, with an 80% 5-year progression-free survival (PFS) in patients between 18 and 64 years old [[1]]. Our group previously showed a 43% two-year overall survival (OS), 27% two-year PFS and 46% of relapses in a cohort of 113 patients with r/r HL with only 2% treated with anti-PD1 before allo-SCT. [Extracted from the article]